ROIV News and Press, Roivant Sciences Ltd.

2024-07-11 10:45:04 ET Rivian Automotive Inc (RIVN) RIVN is trading UP for the last 5 days, and it at trading at $16.74 with volume of 18,885,597 and a one day change of $0.37 (2.23%). Rivian Automotive Inc has a 52-week low of 12.15 and a 52-week high of $32.60. The business's 50-d...

2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...

2024-06-07 18:26:03 ET Summary The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, a...

2024-06-02 17:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-02 07:27:01 ET Summary Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash. The company holds stakes in biotech companies worth billions, including Immunovant and Arbutus. Genevant and Arbutus offer potential litigation valu...

2024-05-30 12:23:06 ET Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Conference Call May 30, 2024, 8:00 AM ET Company Participants Abby Beier - Principal, Strategic Finance Matt Gline - Chief Executive Officer Frank Torti - Managing Director, Vant Chair Mayuk...

2024-05-30 07:08:51 ET More on Roivant Sciences Roivant Sciences: Cashing In On Vants And Ventures Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success Roivant announces $1.5B share buyback, positive Phase 2 data Seeking Alpha’s Quant ...

BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure...

2024-05-29 13:50:15 ET More on Roivant Sciences Roivant Sciences: Cashing In On Vants And Ventures Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success Roivant announces $1.5B share buyback, positive Phase 2 data Seeking Alpha’s Quant ...

2024-05-29 10:50:14 ET Major earnings expected before the bell on Thursday include: Best Buy ( BBY ) Canopy Growth ( CGC ) Dollar General ( DG ) Hormel Foods ( HRL ) Royal Bank of Canada ( RY ) Read the full article on Seeking Alpha Fo...